Regenerative Cell Therapy Articles & Analysis
42 news found
Today, scientists are amassing a new arsenal of magic bullets, and new companies are proliferating to carry them forward in the war against cancer and a host of other diseases and disorders. Advances in cell replacement therapy, for example, are making it possible for scientists to genetically engineer a patient’s own T-cells so they can ...
Senti Bio’s oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow; SENTI-301, a regulatable Multi-Armed off-the-shelf CAR-NK cell ...
CIRM grant awarded to accelerate clinical trial of NRTX-1001, a promising regenerative neuronal cell therapy in adults with drug-resistant seizures NRTX-1001 is the first human cell therapy candidate to enter clinical investigation for the treatment of epilepsy Neurona Therapeutics, a clinical-stage ...
About RepliCel Life Sciences RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These ...
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies to treat chronic neurological disorders, today announced that Cory R. ...
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of preclinical data from its lead inhibitory neuron cell therapy candidate, NRTX-1001. ...
About RepliCel Life Sciences RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions has appointed Mark Borman as Chairman of the Board as Dr. ...
Salt Lake City, UT – February 25, 2022 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the presentation of positive interim data from its ongoing Phase 1/2 ...
InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell therapy, commonly called “stem cell therapy”, to treat orthopedic indications. ...
This peer-reviewed article describes the design of the trial which investigated Lomecel-B, a living cell therapy product, as a regenerative medicine strategy for the treatment of frailty in older adults. ...
” With respect to the newly granted and allowed patents, RepliCel has been issued a key patent in Japan related to the Company's RCT-01 cell therapy for the treatment of chronic tendinopathy and two patents, one in Brazil and another in Mexico, relating to its RCS-01 regenerative cell therapy for skin ...
InGeneron, Inc., a clinical stage biotechnology company, today announced that the American Medical Association’s (AMA) Current Procedural Terminology (CPT®) Editorial Panel has issued two new Category III CPT® codes for the company’s autologous, adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator ...
The dispute between Shiseido and RepliCel is related to a license for Asia to RepliCel’s cell therapy technology for androgenetic alopecia, which is the leading cause of male and female pattern hair loss. ...
About RepliCel Life Sciences RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These ...
“Advancing NRTX-1001, the first of our innovative regenerative neural cell therapies, into the clinic is the culmination of an enormous amount of hard work by the Neurona team and a testament to the leadership of these three individuals. ...
Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to FT516 for the treatment of relapsed / refractory diffuse large B-cell lymphoma (DLBCL). ...
As one of the first results of the collaboration initiated in early 2020 between the Cell Culture and Therapy Laboratory (« LCTC ») of the AP-HM and the Poietis company, this installation is a major milestone in the roadmap to start the first clinical trial of a 3D bioprinted human tissue, which will be a skin substitute bioprinted from ...
ByPoietis
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs. ...
Now RepliCel is on-track to be one of the first foreign regenerative medicine companies based outside of Asia to directly engage in a clinical study of a cell therapy product under the ASRM regulatory pathway to commercialization. ...